ArticleJournal of controlled release : official journal of the Controlled Release Society2014
Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Ultrasound-triggered release of an active Wnt signalling agent (6-bromoindirubin-3-oxime) from perfluorocarbon nanodroplets.RSC pharmaceutics · 2026Article
- A systematic review of microgravity on reproductive systems: Implications for space biology and human health.iScience · 2026Review
- Ultrasound-mediated targeted micro/nanobubbles: breaking new boundaries in precision tumor therapy.International journal of surgery (London, England) · 2026Article
- Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Ultrasound enhanced siRNA delivery using cationic liposome-microbubble complexes for the treatment of squamous cell carcinoma.Nanotheranostics · 2024Article
- Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies.Frontiers in oncology · 2022Review
- Exploration of Site-Specific Drug Targeting-A Review on EPR-, Stimuli-, Chemical-, and Receptor-Based Approaches as Potential Drug Targeting Methods in Cancer Treatment.Journal of oncology · 2022Review
- Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.Nature biomedical engineering · 2021Article
- Targeting the Dysfunctional Placenta to Improve Pregnancy Outcomes Based on Lessons Learned in Cancer.Clinical therapeutics · 2021Review
- Microbubbles and Nanobubbles with Ultrasound for Systemic Gene Delivery.Pharmaceutics · 2020Review
- LncRNA-ATB in cancers: what do we know so far?Molecular biology reports · 2020Review
- Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- New Aspects of Ultrasound-Mediated Targeted Delivery and Therapy for Cancer.International journal of nanomedicine · 2020Review
- Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics.Theranostics · 2020Review
- Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA.Asian journal of pharmaceutical sciences · 2019Review
- Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation EffectTheranostics · 2019Article
- Review
- Recent Progress in Gene Therapy for Ovarian Cancer.International journal of molecular sciences · 2018Review
- A versatile method for the preparation of particle-loaded microbubbles for multimodality imaging and targeted drug delivery.Drug delivery and translational research · 2018Article
- Spiral computed tomography evaluation of rabbit VX2 hepatic tumors treated with 20 kHz ultrasound and microbubbles.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The major drawback hampering siRNA therapies from being more widely accepted in clinical practice is its insufficient accumulation at the target site mainly due to poor cellular uptake and rapid degradation in serum. Therefore, we designed a novel polymeric siRNA carrier system, which would withstand serum-containing environments and tested its performance in vitro as well as in vivo. Delivering siRNA with a system combining an arginine-grafted bioreducible polymer (ABP), microbubbles (MBs), and ultrasound technology (US) we were able to synergize the advantages each delivery system owns individually, and created our innovative siRNA-ABP-MB (SAM) complexes. SAM complexes show significantly higher siRNA uptake and VEGF protein knockdown in vitro with serum-containing media when compared to naked siRNA, and 25k-branched-polyethylenimine (bPEI) representing the current standard in nonviral gene therapy. SAM complexes activated by US are also able to improve siRNA uptake in tumor tissue resulting in decelerating tumor growth in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.